Report Overview

The global secondary hyperparathyroidism (SHPT) treatment market was pegged at US$ 5.12 billion in 2021 and is expected to register a revenue CAGR of 8.70% during the forecast period.

Market Fundamentals

Secondary hyperparathyroidism (SHPT) is a cause of low blood calcium levels brought by an underlying disease that results in the parathyroid glands enlarging and secreting parathyroid hormone (PTH) abnormally. In general, a low-phosphorus diet, phosphate binders, vitamin D derivatives, calcimimetics, and even parathyroidectomy are used to treat secondary hyperparathyroidism. Patients over the age of 60 are more likely to develop hyperparathyroidism than others. However, it is also seen in the younger age groups. The condition is more likely to affect women than men. The risk factors for hypoparathyroidism involve previous thyroid or neck surgery, a family history of the parathyroid disorder, or specific autoimmune endocrine conditions such as Addison’s disease.

[36346346]

Market Dynamics

The increasing frequency in the uptake of SHPT drugs is due to its high prevalence mostly seen in people with renal diseases. Significant rise in diabetes leading to many renal conditions, and severe vitamin D deficiency are thus the key revenue growth drivers of the SHPT market. The revenue growth of the global secondary hyperparathyroidism treatment market can be challenged due to certain side effects, such as muscle spasms,  diarrhea, and nausea, which are frequently associated with secondary hyperparathyroidism therapy.

Market Ecosystem

The global secondary hyperparathyroidism (SHPT) treatment market has been analyzed from three perspectives: drug class, distribution channel, and region. 

Secondary Hyperparathyroidism (SHPT) Treatment Market by Drug Class

[5634523] 

Based on drug class, the global market for secondary hyperparathyroidism (SHPT) treatment is segmented into vitamin D analogues, phosphate binders, and calcimimetics. 

The vitamin D analogues segment dominates the global market in terms of revenue share. The main aim of vitamin D analogues treatment is to reduce circulating PTH levels and promote osteoid calcification. The development of several vitamin D analogues that preserve direct suppressive action of 1,25(OH) (2)D(3) on the parathyroid glands and having low calcemic activity, is offering proper management for secondary hyperthyroidism being a safer and more efficient treatment. 

Other segments are also expected to register high revenue growth such as phosphate binders, which effectively reduce blood and urine phosphorus in patients with chronic kidney diseases that have normal or near-normal levels of serum phosphorus. They also reduce the evolution of secondary hyperparathyroidism and speed up the process of vascular calcification. Calcimimetics offer a method to manage serum parathyroid hormone levels in secondary hyperparathyroidism without raising the calcium-phosphorus output, and more importantly, they may reduce the risk for VC (Vascular Calcification) in the patients.

Secondary Hyperparathyroidism (SHPT) Treatment Market by Distribution Channel 

Based on distribution channel, the global market for secondary hyperthyroidism is segmented into hospital & retail pharmacies, clinics, and online channels. 

The hospital & retail pharmacy segment dominates the market for secondary hyperparathyroidism in terms of market revenue share. These are a significant source of secondary hyperparathyroidism therapeutics due to the steady rise in the number of dialysis facilities across the country and the accessibility of SHPT (Secondary hyperparathyroidism) therapeutics at significant discounts in hospital pharmacies.

The online channel segment is also expected to grow in the terms of revenue during the forecast period. The fundamental factor is that a significant number of distributors have increased their financial commitment to the growth of the e-pharmacy network. 

 Secondary Hyperparathyroidism (SHPT) Treatment Market by Region 

Based on the region, the global secondary hyperparathyroidism (SHPT) treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. 

In terms of revenue share, North America dominates the global secondary hyperparathyroidism (SHPT) treatment market. The high revenue growth is owing to the increased research and development of novel therapeutics, the high prevalence of renal diseases, and the presence of major market players in this region. SHPT is commonly managed with Sensipar (Cinacalcet), a popular drug manufactured by Amgen. 

Europe is expected to be the second largest contributor to the global secondary hyperparathyroidism treatment market in terms of revenue share. The presence of a large patient population and increased awareness are major factors influencing the market revenue growth in this region. 

The Asia Pacific region for the global secondary hyperparathyroidism treatment market is expected to register significant revenue growth during the forecast period because of the launch of new effective drugs in this region and the increased number of clinical studies on the diseases. Additionally, the presence of many drugs in the pipelines is also expected to boost the market revenue growth during the forecast period.     

Competitive Landscape

The prominent players operating in the global secondary hyperparathyroidism (SHPT) treatment market are:

• Cipla Inc. 
• Teva Pharmaceuticals Industries Ltd. 
• AbbVie Inc.
• Dr. Reddy’s Laboratories Ltd. 
• Amgen Inc. 
• OPKO Health, Inc. 
• Sanofi S.A. 
• Kyowa Hakko Kirin Co. Ltd.
• KAI Pharmaceuticals Inc. 
• Astellas Pharma, Inc. 

Frequently Asked Questions About This Report